Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

8 trials in Phase 3/4

Results Transparency

77%

10 of 13 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

Phase 3
8(57.1%)
Phase 2
6(42.9%)
14Total
Phase 3(8)
Phase 2(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT05646719Phase 3Completed

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

Role: lead

NCT07140783Phase 3Active Not Recruiting

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

Role: lead

NCT04692688Phase 2Completed

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Role: lead

NCT06349759Phase 3Completed

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

Role: lead

NCT06542497Phase 3Completed

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

Role: lead

NCT04638660Phase 3Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Role: lead

NCT04675151Phase 2Completed

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Role: lead

NCT04004507Phase 2Completed

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

Role: lead

NCT03960866Phase 2Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Role: lead

NCT04620213Phase 3Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Role: lead

NCT05223478Phase 3Completed

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

Role: lead

NCT04024891Phase 2Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Role: lead

NCT05134974Phase 3Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

Role: lead

NCT01703559Phase 2Completed

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Role: lead

All 14 trials loaded